PDF(3208 KB)
Bioinformatics analysis on key genes related to prognosis, diagnosis, and immune cell infiltration of hepatocellular carcinoma and their potential therapeutic drugs
Jinlian LI,Lanzhen HUANG,Xishi HUANG,Kangzhi LI,Jiali JIANG,Miaomiao ZHANG,Qunying WU
PDF(3208 KB)
PDF(3208 KB)
Bioinformatics analysis on key genes related to prognosis, diagnosis, and immune cell infiltration of hepatocellular carcinoma and their potential therapeutic drugs
Objective To screen the key genes related to the prognosis, diagnosis, and immune infiltration of the hepatocellular carcinoma (HCC) patients by bioinformatics analysis methods, and to analyze their potential therapeutic drugs. Methods The HCC gene expression profile data and corresponding clinical informations of the HCC patients were downloaded from the Gene Expression Omnibus (GEO) database and The Cancer Genome Atlas (TCGA) database. The R software package limma was used to screen the differentially expressed genes (DEGs) in HCC. Gene Ontology (GO) functional enrichment analysis and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analysis were performed on the DEGs. The STRING database was used to construct the protein-protein interaction (PPI) network; the Cytoscape software was used to visualize the PPI network and screen the key genes; Kaplan-Meier survival curve and LASSO regression algorithm were used to identify the key genes related to the HCC prognosis;external data sets were used to validate their expressions and analyze the diagnostic efficacy;CIBERSORT algorithm was used to detect the relationship between the expression of prognosis-related key genes and HCC immune cell infiltration. The MiRNet and Network Analyst databases were used to construct the microRNA (miRNA)-key gene mRNA and transcription factors (TFs)-key gene mRNA molecular regulatory networks; CMap database was used to screen the potential small molecule drugs for HCC treatment. Results A total of 146 DEGs were screened, including 30 upregulated genes and 116 downregulated genes. The GO functional enrichment analysis and KEGG pathway enrichment analysis results showed that the DEGs were significantly enriched in biological processes (BP) such as steroid, alkene compound, and hormone metabolism, as well as signaling pathways such as retinol metabolism, drug metabolism-cytochrome P450 (CYP450), complement and coagulation cascades. The PPI network analysis identified 14 key genes, among which formimidoyltransferase cyclodeaminase (FTCD), secreted phosphoprotein 2 (SPP2), thrombin-antithrombin complex (TAT), complement C6 (C6), and cytochrome CYP450 family member 2C9 (CYP2C9) were significantly associated with the prognosis, clinical pathological stage, and histological grade of the HCC patients and also had high diagnostic efficacy for HCC and were closely related to immune cell infiltration in HCC. Hsa-mir-182-5p, CUT-like homeobox 1 (CUX1), early growth response 1 (EGR1), SMAD family member 4 (SMAD4), and tumor protein P53 (TP53) were identified as the important regulators targeting the above-mentioned prognosis-related key genes. DL-thiorphan, promethazine, and apigenin may have the therapeutic effects on HCC. Conclusion FTCD, SPP2, TAT, C6, and CYP2C9 may be the potential targets for the diagnosis, prognosis, and treatment of HCC. Three predicted small molecule drugs, DL-thiorphan, promethazine, and apigenin, may provide the references for the development of therapeutic drugs for HCC.
Hepatocellular carcinoma / Biomarker / Small molecule drug / Bioinformatics
Q811.4
| 1 | BRAY F, FERLAY J, SOERJOMATARAM I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2018, 68(6): 394-424. |
| 2 | LLOVET J M, KELLEY R K, VILLANUEVA A, et al. Hepatocellular carcinoma[J]. Nat Rev Dis Primers, 2021, 7(1): 6. |
| 3 | MALUCCIO M, COVEY A. Recent progress in understanding, diagnosing, and treating hepatocellular carcinoma[J]. CA Cancer J Clin, 2012, 62(6): 394-399. |
| 4 | BURKHART R A, RONNEKLEIV-KELLY S M, PAWLIK T M. Personalized therapy in hepatocellular carcinoma: molecular markers of prognosis and therapeutic response[J]. Surg Oncol, 2017, 26(2): 138-145. |
| 5 | LI B H, XU T C, LIU C H, et al. Liver-enriched genes are associated with the prognosis of patients with hepatocellular carcinoma[J]. Sci Rep, 2018, 8(1): 11197. |
| 6 | NAULT J C, REYNIèS A D, VILLANUEVA A, et al. A hepatocellular carcinoma 5-gene score associated with survival of patients after liver resection[J]. Gastroenterology, 2013, 145(1): 176-187. |
| 7 | TU J X, CHEN J J, HE M M, et al. Bioinformatics analysis of molecular genetic targets and key pathways for hepatocellular carcinoma[J]. Onco Targets Ther, 2019, 12: 5153-5162. |
| 8 | 刘 迁, 祁国萍, 于华裔, 等. 结肠癌核心基因和独立预后因子筛选的生物信息学分析[J]. 吉林大学学报(医学版), 2022, 48(3): 755-765. |
| 9 | 李 楠, 陈 蕾, 许天敏, 等. 子宫内膜异位症患者细胞外基质相关基因筛选的生物信息学分析[J]. 吉林大学学报(医学版), 2022, 48(1): 188-194. |
| 10 | RITCHIE M E, PHIPSON B, WU D, et al. Limma powers differential expression analyses for RNA-sequencing and microarray studies[J]. Nucleic Acids Res, 2015, 43(7): e47. |
| 11 | MANDREKAR J N. Receiver operating characteristic curve in diagnostic test assessment[J]. J Thorac Oncol, 2010, 5(9): 1315-1316. |
| 12 | LI M H, XIN S Y, GU R Y, et al. Novel diagnostic biomarkers related to oxidative stress and macrophage ferroptosis in atherosclerosis[J]. Oxid Med Cell Longev, 2022, 2022: 8917947. |
| 13 | SHEN L, ZHOU K G, LIU H, et al. Prediction of mechanosensitive genes in vascular endothelial cells under high wall shear stress[J]. Front Genet, 2021, 12: 796812. |
| 14 | WANG Y Y, KANG H E, XU T Y, et al. CeDR Atlas: a knowledgebase of cellular drug response[J]. Nucleic Acids Res, 2022, 50(D1): D1164-D1171. |
| 15 | SNAEBJORNSSON M T, JANAKI-RAMAN S, SCHULZE A. Greasing the wheels of the cancer machine: the role of lipid metabolism in cancer[J]. Cell Metab, 2020, 31(1): 62-76. |
| 16 | CHAN A W, GILL R S, SCHILLER D, et al. Potential role of metabolomics in diagnosis and surveillance of gastric cancer[J]. World J Gastroenterol, 2014, 20(36): 12874-12882. |
| 17 | CHENG X G, GU J, KLAASSEN C D. Adaptive hepatic and intestinal alterations in mice after deletion of NADPH-cytochrome P450 Oxidoreductase (Cpr) in hepatocytes[J]. Drug Metab Dispos, 2014, 42(11): 1826-1833. |
| 18 | YAN T M, LU L L, XIE C, et al. Severely impaired and dysregulated cytochrome P450 expression and activities in hepatocellular carcinoma: implications for personalized treatment in patients[J]. Mol Cancer Ther, 2015, 14(12): 2874-2886. |
| 19 | YU Z H, GE Y Y, XIE L, et al. Using a yeast two-hybrid system to identify FTCD as a new regulator for HIF-1α in HepG2 cells[J]. Cell Signal, 2014, 26(7): 1560-1566. |
| 20 | LU C Y, FANG S J, WENG Q Y, et al. Integrated analysis reveals critical glycolytic regulators in hepatocellular carcinoma[J]. Cell Commun Signal, 2020, 18(1): 97. |
| 21 | FU L, DONG S S, XIE Y W, et al. Down-regulation of tyrosine aminotransferase at a frequently deleted region 16q22 contributes to the pathogenesis of hepatocellular carcinoma[J]. Hepatology, 2010, 51(5): 1624-1634. |
| 22 | WANG Q, TANG Q, ZHAO L J, et al. Time serial transcriptome reveals Cyp2c29 as a key gene in hepatocellular carcinoma development[J]. Cancer Biol Med, 2020, 17(2): 401-417. |
| 23 | ROUMENINA L T, DAUGAN M V, PETITPREZ F, et al. Context-dependent roles of complement in cancer[J]. Nat Rev Cancer, 2019, 19(12): 698-715. |
| 24 | HOBART M J, FERNIE B A, DISCIPIO R G, et al. A physical map of the C6 and C7 complement component gene region on chromosome 5p13[J]. Hum Mol Genet, 1993, 2(7): 1035-1036. |
| 25 | OKA R, SASAGAWA T, NINOMIYA I, et al. Reduction in the local expression of complement component 6 (C6) and 7 (C7) mRNAs in oesophageal carcinoma[J]. Eur J Cancer, 2001, 37(9): 1158-1165. |
| 26 | WANG Z, LIAO J, WU S, et al. Recipient C6 rs9200 genotype is associated with hepatocellular carcinoma recurrence after orthotopic liver transplantation in a Han Chinese population[J]. Cancer Gene Ther, 2016, 23(6): 157-161. |
| 27 | GARNELO M, TAN A, HER Z, et al. Interaction between tumour-infiltrating B cells and T cells controls the progression of hepatocellular carcinoma[J]. Gut, 2017, 66(2): 342-351. |
| 28 | CHEN Q F, LI W, WU P H, et al. Significance of tumor-infiltrating immunocytes for predicting prognosis of hepatitis B virus-related hepatocellular carcinoma[J]. World J Gastroenterol, 2019, 25(35): 5266-5282. |
| 29 | KUANG D M, PENG C, ZHAO Q Y, et al. Activated monocytes in peritumoral stroma of hepatocellular carcinoma promote expansion of memory T helper 17 cells[J]. Hepatology, 2010, 51(1): 154-164. |
| 30 | SUN K, WANG L, ZHANG Y Y. Dendritic cell as therapeutic vaccines against tumors and its role in therapy for hepatocellular carcinoma[J]. Cell Mol Immunol, 2006, 3(3): 197-203. |
| 31 | WEI L, WANG X W, LV L Y, et al. The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma[J]. Mol Cancer, 2019, 18(1): 147. |
| 32 | VAN KEUREN-JENSEN K R, MALENICA I, COURTRIGHT A L, et al. MicroRNA changes in liver tissue associated with fibrosis progression in patients with hepatitis C[J]. Liver Int, 2016, 36(3): 334-343. |
| 33 | CAO M Q, YOU A B, ZHU X D, et al. MiR-182-5p promotes hepatocellular carcinoma progression by repressing FOXO3a[J]. J Hematol Oncol, 2018, 11(1): 12. |
| 34 | LAMBERT S A, JOLMA A, CAMPITELLI L F, et al. The human transcription factors[J]. Cell, 2018, 175(2): 598-599. |
| 35 | WU Q, ZHANG B, SUN Y D, et al. Identification of novel biomarkers and candidate small molecule drugs in non-small-cell lung cancer by integrated microarray analysis[J]. Onco Targets Ther, 2019, 12: 3545-3563. |
/
| 〈 |
|
〉 |